Guardant Health (GH) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Guardant Health (GH) has outperformed Natera (NTRA) over the past year, gaining 165.3% versus a gain of 134.7%. Over five years, NTRA leads with a +257.1% price change compared with +65.7% for GH. Natera is the larger company by market cap ($55.56 billion vs $22.10 billion), about 2.5 times the size.
Natera converts more of its revenue into profit, with a net margin of -9.0% versus -42.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GH | NTRA |
|---|---|---|
| Share price | $164.71 | $385.47 |
| Market cap | $22.10B | $55.56B |
| 1-day change | -2.15% | -2.55% |
| YTD return | +64.80% | +72.67% |
| 1-year return | +165.34% | +134.71% |
| 5-year return | +65.68% | +257.10% |
| EPS (TTM) | $-3.50 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $982.02M | $2.31B |
| Revenue growth (YoY) | +32.88% | +35.90% |
| Net income (latest FY) | $-416.28M | $-208.16M |
| Gross margin | 64.46% | — |
| Operating margin | -44.53% | -13.44% |
| Net margin | -42.39% | -9.03% |
| 52-week high | $191.05 | $437.41 |
| 52-week low | $61.00 | $167.99 |
| Distance from 52-week high | -13.79% | -11.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +21.33% | -2.09% |
| Average volume | 2.02M | 1.44M |
| Shares outstanding | 134.20M | 144.14M |
| Employees | 2,490 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Natera is about 2.5 times larger than Guardant Health by market value ($55.56B vs $22.10B).
- GH has outperformed NTRA by 30.6 percentage points over the past year.
- Natera is more profitable, keeping -9.0 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
GH vs NTRA FAQ
Which is bigger, Guardant Health or Natera?
Natera (NTRA) is larger, with a market capitalization of $55.56B compared with $22.10B for Guardant Health (GH).
Which stock has performed better over the past year, GH or NTRA?
GH returned +165.34% over the past 12 months, compared with +134.71% for NTRA (price return, excluding dividends). Past performance does not predict future results.
Are Guardant Health and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.